

# Wondfo BGA-102 Introduction

International Market Dept. 07-07

#### What is Blood Gas Analysis for?

- Blood gas analysis is a key component of emergency diagnostic procedures.
- It allows physicians to quickly assess the patient's oxygen status and acid-base metabolism.





#### **Blood Gas Analysis Product Line**











1. BGA-102

2. Reagent Pack

3. Test Card

4. QC Solution


5. Electronic QC Card

## **Instrument Specification**



Instrument	Specification		
Model	Blood Gas Analyzer (BGA-102)		
Dimension & Weight	302*226*180mm(L*W*H), <6.5 kg (including battery)		
Display	8 inches, resistive touchscreen		
Power Supply	220V, 1.2~0.5A, 50Hz		
Battery (Lithium)	14.8V/5000mAh, 8 hours stand by / 50 times testing		
Storage	50,000 test results, 1 Gigabyte		
Barcode scanner	Built-in barcode scanner		
Results output	Built-in thermal printer (58*30mm), Wired connection, WIFI, LIS and Data management system		
Temperature control	37°C±0.2°C		
Working environment	Temperature: 10°C~30°C Humidity: 25%~80% Atmospheric Pressure: 70-106.6kPa Altitude: 500~3000m		

#### **Reagent Pack**



#### **Test Capacity**

50 Tests 100 Tests

#### **Notice**

The QR code is for single use Prior to installation, please put the reagent pack in room temperature for at least 8 hours

#### **Test Card**

#### **Specifications**

#### Model Test parameters

W459 PH/PCO<sub>2</sub>/PO<sub>2</sub>

W460 K+/NA+/CI-

W461 K+/NA+/ CI-/CA++

W462 PH/PCO<sub>2</sub>/PO<sub>2</sub>/K<sup>+</sup>/NA<sup>+</sup>/CI<sup>-</sup>

W463 PH/PCO<sub>2</sub>/PO<sub>2</sub>/K<sup>+</sup>/NA<sup>+</sup>/Cl<sup>-</sup>/HCT


W464 PH/PCO<sub>2</sub>/PO<sub>2</sub>/K<sup>+</sup>/NA<sup>+</sup>/CA<sup>++</sup>/HCT

W465 PH/PCO<sub>2</sub>/PO<sub>2</sub>/K<sup>+</sup>/NA<sup>+</sup>/Cl<sup>-</sup>/CA<sup>++</sup>/HCT

W466  $PH/PCO_2/PO_2/K^+/NA^+/CI^-/CA^{++}/HCT/Glu/Lac$ 

#### **Shelf-life**

Catalog No.	Stored at 4~30°C	Refrigerated at 2~8°C	Number of Testing Parameters
W466-C7P4-M W466-C7P4-E	Valid for 9 months	Valid for 12 months	For testing 10 parameters including Glu/Lac
All others except for above two	Valid for 12 months	Valid for 15 months	For testing 3~8 parameters excluding Glu/Lac



## **Test specification**

Test Item	Measuring Range	Reference Range
рН	6.500-8.000	7.35-7.45
pCO2	10-150mmHg	35.0-45.0mmHg 4.67-6.00kPa
pO2	10-700mmHg	83-108 mmHg 11.039-14.364kPa
Na+	90-180mmol/L	136-146mmol/L
K+	1.6-11.5mmol/L	3.4-4.5 mmol/L
<b>C</b> a++	0.25-3.00mmol/L	1.15-1.29mmol/L
CI-	65-140mmol/L	98-106 mmol/L
Hct	10-75%PCV	Male 42-49%pcv Female 37-43%pcv
Glu	1.1-38.9mmol/L	3.9-5.8 mmol/L
Lac	0.30-20.00mmol/L	3.9-5.8 mmol/L 0.5-1.6 mmol/L

Sample type/volume: Arterial blood, 1mL syringe 400µL / 2mL syringe 800µL

Wondfo Test specification

Calculation parameter	Description	Calculation parameter	Description
cH⁺	Concentration of hydrogen ion	AnGap	Interval of anion
cH <sup>+</sup> (T)	Concentration of hydrogen ion after temperature revision	tHb(est)	Total hemoglobin (estimated value)
pH(T)	PH value after temperature revision	SO2(est)	Oxyhemoglobin saturation (estimated value)
pCO2(T)	Partial pressure of carbon dioxide after temperature revision	pO2(A-a)	Partial oxygen pressure difference between pulmonary alveoli and artery
pO2(T)	Partial pressure of oxygen after temperature revision	pO2(A-a)(T)	Partial oxygen pressure difference between pulmonary alveoli and artery after temperature revision
HCO <sub>3</sub> - act	Actual concentration of bicarbonate radical	pO2(a/A)	Oxygen tension ration between pulmonary alveoli and artery
HCO₃⁻ std	Standard concentration of bicarbonate radical	pO2(a/A) (T)	Oxygen tension ration between pulmonary alveoli and artery after temperature revision
BB(B)	Buffer base in blood	RI	Respiratory index
BE(B)	Residue base in blood	RI(T)	Respiratory index after temperature revision
BE(ecf)	Residue base in blood  Residue base in extracellular fluid	PO2/FIO2	The ratio between oxygen partial pressure and the part of inhaled oxygen
ctCO2	Total concentration of carbon dioxide	PO2(T)/FIO2	The ratio between oxygen partial pressure and the part of inhaled oxygen after temperature revision
Ca <sup>++</sup> (7.4)	The concentration of calcium ion when the PH value is 7.4		

#### **User-friendly Operation**



**Training** 

Intuitive operation animation, needs no extra training



Patient Info.

Support to input patient's information by manual or barcode scanning.



SOP

Easy and standard operation, ensure accurate test result

#### **BGA Guideline**

#### AARC Clinical Practice Guideline: Blood Gas Analysis and Hemoximetry: 2013

Michael D Davis RRT, Brian K Walsh RRT-NPS RPFT FAARC, Steve E Sittig RRT-NPS FAARC, and Ruben D Restrepo MD RRT FAARC

#### **BGA 2.0 SETTING**

Blood gas analysis should be performed by trained individuals, 16,17 in a variety of settings, including, but not limited to:

- **2.1** hospital laboratory
- 2.2 hospital emergency department
- **2.3** patient-care area
- **2.4** clinic laboratory
- 2.5 laboratory in physician's office<sup>16</sup>
- 2.6 inter-facility critical care transport<sup>18,19</sup>
- **2.7** pulmonary diagnostic laboratory
- **2.8** operating room suite
- **2.9** cardiac catheterization laboratory<sup>20</sup>
- 2.10 postmortem examination<sup>21</sup>

#### **Indications**

- Indications for BGA and hemoximetry include:
  - The need to further evaluate the adequacy of a patient's ventilatory (P<sub>aCO2</sub>), acid-base (pH), and oxygenation (P<sub>aO2</sub> and oxyhemoglobin saturation) status, the oxygen-carrying capacity (P<sub>aO2</sub>, oxyhemoglobin saturation, total hemoglobin, and dyshemoglobin saturations) and intrapulmonary shunt
  - The need to quantify the response to therapeutic intervention (e.g., supplemental oxygen administration, mechanical ventilation) or diagnostic evaluations (e.g., exercise desaturation)
  - The need to assess early goal-directed therapy measuring central venous oxygen saturation in patients with sepsis, septic shock and after major surgery
  - The need to monitor severity and progression of documented disease processes
  - The need to assess inadequacy of circulatory response
    - A high central venous/arterial P<sub>CO2</sub> difference can indicate inadequate perfusion, as observed in severe hemorrhagic shock, poor cardiac output, during cardiopulmonary resuscitation, and after cardiopulmonary bypass.
  - The need to assess acid-base status when an arterial blood gas cannot be obtained. A central venous sample or capillary sample is preferable to a peripheral venous sample. A peripheral venous sample reflects only local tissue consumption versus delivery.
    - When analyzed by an accurate instrument and in very specific clinical conditions, an adjusted central VBG or CBG may show sufficient agreement with some parameters of the ABG.
    - VBG and CBG analysis has been found to reliably predict the ABG values of pH, P<sub>CO2</sub>, and HCO<sub>3</sub> in patients with exacerbation of chronic obstructive pulmonary disease (COPD).
    - A peripheral venous blood sample can be used to evaluate the acid-base status in patients with uremia and diabetic ketoacidosis.

#### **BGA Guideline for COVID-19**

#### Clinical management of COVID-19

Interim guidance 27 May 2020

Table 2. COVID-19 disease severity



## Mild disease Symptomatic patients (Table 1) meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia. See the WHO website for most up-to-date case definitions (1). Moderate disease Pneumonia Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO₂ ≥ 90% on room air (54). Child with clinical signs of non-severe pneumonia (cough or difficulty breathing + fast breathing and/or chest indrawing) and no signs of severe

Fast breathing (in breaths/min): < 2 months: ≥ 60; 2–11 months: ≥ 50;

pneumonia.

1-5 years: ≥ 40 (55).

While the diagnosis can be made on clinical grounds; chest imaging (radiograph, CT scan, ultrasound) may assist in diagnosis and identify or exclude pulmonary complications.

#### Severe disease

#### Severe pneumonia

Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress or SpO<sub>2</sub> < 90% on room air (54).

**Child** with clinical signs of pneumonia (cough or difficulty in breathing) + at least one of the following:

- Central cyanosis or SpO<sub>2</sub> < 90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions (55.56).
- Fast breathing (in breaths/min): < 2 months: ≥ 60; 2–11 months: ≥ 50;</li>
   1–5 years: ≥ 40 (55).

While the diagnosis can be made on clinical grounds; chest imaging (radiograph, CT scan, ultrasound) may assist in diagnosis and identify or exclude pulmonary complications.

#### Critical disease

#### Acute respiratory distress syndrome (ARDS) (57-59)

Onset: within 1 week of a known clinical insult (i.e. pneumonia) or new or worsening respiratory symptoms.

Chest imaging: (radiograph, CT scan, or lung ultrasound): bilateral opacities, not fully explained by volume overload, lobar or lung collapse, or nodules.

Origin of pulmonary infiltrates: respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic cause of infiltrates/oedema if no risk factor present.

#### Oxygenation impairment in adults (57, 59):

- Mild ARDS: 200 mmHg < PaO<sub>2</sub>/FiO<sub>2</sub><sup>a</sup> ≤ 300 mmHg (with PEEP or CPAP ≥ 5 cmH<sub>2</sub>O).<sup>b</sup>
- Moderate ARDS: 100 mmHg < PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 200 mmHg (with PEEP ≥ 5 cmH<sub>2</sub>O).<sup>b</sup>
- Severe ARDS: PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 100 mmHg (with PEEP ≥ 5 cmH<sub>2</sub>O).<sup>b</sup>

Oxygenation impairment in children: note OI and OSI.° Use OI when available. If  $PaO_2$  not available, wean  $FiO_2$  to maintain  $SpO_2 \le 97\%$  to calculate OSI or  $SpO_2/FiO_2$  ratio:

- Bilevel (NIV or CPAP) ≥ 5 cmH<sub>2</sub>O via full face mask: PaO<sub>2</sub>/FiO<sub>2</sub>
   ≤ 300 mmHg or SpO<sub>2</sub>/FiO<sub>2</sub> ≤ 264.
- Mild ARDS (invasively ventilated):  $4 \le OI < 8$  or  $5 \le OSI < 7.5$ .
- Moderate ARDS (invasively ventilated): 8 ≤ OI < 16 or 7.5 ≤ OSI</li>
   < 12.3.</li>
- Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3.


### **Clinical Application Scenarios**



















## THANK YOU!



